BIO-TECHNE Corp Payments to Acquire Debt Securities, Available-for-sale
BIO-TECHNE Corp (TECH) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 9-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-24
- BIO-TECHNE Corp payments to acquire debt securities, available-for-sale for the quarter ending 2025-03-31 was $0.00.
- BIO-TECHNE Corp payments to acquire debt securities, available-for-sale for the quarter ending 2024-06-30 was $0.00.
- BIO-TECHNE Corp payments to acquire debt securities, available-for-sale for the quarter ending 2024-03-31 was $0.00.
- BIO-TECHNE Corp payments to acquire debt securities, available-for-sale for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- BIO-TECHNE Corp payments to acquire debt securities, available-for-sale for fiscal 2024 was $5.53M, a 73.04% decline from fiscal 2023.
- BIO-TECHNE Corp payments to acquire debt securities, available-for-sale for fiscal 2023 was $20.50M, a 61.32% decline from fiscal 2022.
- BIO-TECHNE Corp payments to acquire debt securities, available-for-sale for fiscal 2022 was $53.00M, a 33.55% increase from fiscal 2021.
- BIO-TECHNE Corp payments to acquire debt securities, available-for-sale for fiscal 2021 was $39.68M, a 43.46% decline from fiscal 2020.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-08 | $0.00 10-Q · filed 2025-05-08 | ||
| 2024-12-31 | $0.00 10-Q · filed 2025-02-06 | |||
| 2024-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $0.00 derived: sum of 2 quarters · filed 2026-08-24 | $5.53M 10-K · filed 2026-08-24 | |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-08 | $5.53M 10-Q · filed 2025-05-08 | ||
| 2023-12-31 | $5.53M 10-Q · filed 2025-02-06 | |||
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $0.00 derived: sum of 2 quarters · filed 2025-08-22 | $6.00M derived: sum of 3 quarters · filed 2025-08-22 | $20.50M 10-K · filed 2025-08-22 |
| 2023-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-06 | $6.00M derived: sum of 2 quarters · filed 2024-05-06 | $20.50M 10-Q · filed 2024-05-06 | $25.50M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-12-31 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-07 | $20.50M 10-Q · filed 2024-02-07 | $25.50M derived: sum of 3 quarters · filed 2024-08-22 | $60.00M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-09-30 | $14.50M 10-Q · filed 2023-11-07 | $19.50M derived: sum of 2 quarters · filed 2024-08-22 | $54.00M derived: sum of 3 quarters · filed 2024-08-22 | $54.00M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-06-30 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22 | $39.50M derived: sum of 2 quarters · filed 2024-08-22 | $39.50M derived: sum of 3 quarters · filed 2024-08-22 | $53.00M 10-K · filed 2024-08-22 |
| 2022-03-31 | $34.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-08 | $34.50M derived: sum of 2 quarters · filed 2023-05-08 | $48.00M 10-Q · filed 2023-05-08 | $48.00M derived: sum of 4 quarters · filed 2023-08-23 |
| 2021-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-07 | $13.50M 10-Q · filed 2023-02-07 | $13.50M derived: sum of 3 quarters · filed 2023-08-23 | $26.00M derived: sum of 4 quarters · filed 2023-08-23 |
| 2021-09-30 | $13.50M 10-Q · filed 2022-11-07 | $13.50M derived: sum of 2 quarters · filed 2023-08-23 | $26.00M derived: sum of 3 quarters · filed 2023-08-23 | $26.95M derived: sum of 4 quarters · filed 2023-08-23 |
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23 | $12.50M derived: sum of 2 quarters · filed 2023-08-23 | $13.45M derived: sum of 3 quarters · filed 2023-08-23 | $39.68M 10-K · filed 2023-08-23 |
| 2021-03-31 | $12.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-09 | $13.45M derived: sum of 2 quarters · filed 2022-05-09 | $39.68M 10-Q · filed 2022-05-09 | |
| 2020-12-31 | $945.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-07 | $27.18M 10-Q · filed 2022-02-07 | ||
| 2020-09-30 | $26.24M 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | $70.19M 10-K · filed 2022-08-24 | |||
| 2011-12-31 | $49.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-07 | $84.04M 10-Q · filed 2012-02-07 | $103.89M derived: sum of 3 quarters · filed 2012-02-07 | $154.82M derived: sum of 4 quarters · filed 2012-02-07 |
| 2011-09-30 | $34.31M 10-Q · filed 2011-11-09 | $54.15M derived: sum of 2 quarters · filed 2011-11-09 | $105.09M derived: sum of 3 quarters · filed 2011-11-09 | $142.75M derived: sum of 4 quarters · filed 2012-02-07 |
| 2011-06-30 | $19.84M derived: 10-K 12 month − 10-Q 9 month · filed 2011-08-29 | $70.78M derived: sum of 2 quarters · filed 2011-08-29 | $108.44M derived: sum of 3 quarters · filed 2012-02-07 | $151.37M 10-K · filed 2011-08-29 |
| 2011-03-31 | $50.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-05-10 | $88.59M derived: sum of 2 quarters · filed 2012-02-07 | $131.52M 10-Q · filed 2011-05-10 | $184.01M derived: sum of 4 quarters · filed 2012-02-07 |
| 2010-12-31 | $37.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-07 | $80.59M 10-Q · filed 2012-02-07 | $133.08M derived: sum of 3 quarters · filed 2012-02-07 | $244.79M derived: sum of 4 quarters · filed 2012-02-07 |
| 2010-09-30 | $42.93M 10-Q · filed 2011-11-09 | $95.42M derived: sum of 2 quarters · filed 2011-11-09 | $207.13M derived: sum of 3 quarters · filed 2011-11-09 | $213.19M derived: sum of 4 quarters · filed 2011-11-09 |
| 2010-06-30 | $52.49M derived: 10-K 12 month − 10-Q 9 month · filed 2011-08-29 | $164.20M derived: sum of 2 quarters · filed 2011-08-29 | $170.26M derived: sum of 3 quarters · filed 2011-08-29 | $176.62M 10-K · filed 2011-08-29 |
| 2010-03-31 | $111.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-05-10 | $117.77M derived: sum of 2 quarters · filed 2011-05-10 | $124.13M 10-Q · filed 2011-05-10 | |
| 2009-12-31 | $6.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-02-09 | $12.42M 10-Q · filed 2011-02-09 | ||
| 2009-09-30 | $6.37M 10-Q · filed 2010-11-09 | |||
| 2009-06-30 | $49.17M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |